IMMUNOSTIMULATORY NUCLEIC ACIDS
    15.
    发明申请
    IMMUNOSTIMULATORY NUCLEIC ACIDS 审中-公开
    免疫球蛋白

    公开(公告)号:US20090191188A1

    公开(公告)日:2009-07-30

    申请号:US12393866

    申请日:2009-02-26

    摘要: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.

    摘要翻译: 本发明涉及免疫刺激性核酸组合物和使用该组合物的方法。 富含T的核酸含有多T序列和/或具有大于25%的T核苷酸残基。 TG核酸具有TG二核苷酸。 富含C的核酸具有至少一个多C区和/或大于50%c核苷酸。 这些免疫刺激性核酸以与含有CpG基序的核酸类似的方式起作用。 本发明还包括优选的CpG核酸。

    CPG-like nucleic acids and methods of use thereof
    16.
    发明申请
    CPG-like nucleic acids and methods of use thereof 审中-公开
    CPG样核酸及其使用方法

    公开(公告)号:US20080226649A1

    公开(公告)日:2008-09-18

    申请号:US11725339

    申请日:2007-03-19

    摘要: Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.

    摘要翻译: 提供描述为CpG样核酸的免疫刺激组合物,包括具有CpG核酸的免疫刺激特性的核酸,尽管CpG二核苷酸的C,G或C和G的某些取代。 取代可以包括C的甲基化C,G的肌苷和CpG的ZpY,其中Z是胞嘧啶或dSpacer,Y是肌苷,2-氨基嘌呤,星云素或dSpacer。 还提供了使用CpG样核酸在受试者中诱导免疫应答的方法。 该方法在治疗感染性疾病,过敏症,哮喘,癌症,贫血,血小板减少症或中性粒细胞减少症风险的受试者中是有用的。